JP2021505591A5 - - Google Patents

Download PDF

Info

Publication number
JP2021505591A5
JP2021505591A5 JP2020530675A JP2020530675A JP2021505591A5 JP 2021505591 A5 JP2021505591 A5 JP 2021505591A5 JP 2020530675 A JP2020530675 A JP 2020530675A JP 2020530675 A JP2020530675 A JP 2020530675A JP 2021505591 A5 JP2021505591 A5 JP 2021505591A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
inhibitor
group
motomeko
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020530675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505591A (ja
JP7346408B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/001459 external-priority patent/WO2019111048A1/en
Publication of JP2021505591A publication Critical patent/JP2021505591A/ja
Publication of JP2021505591A5 publication Critical patent/JP2021505591A5/ja
Priority to JP2023144093A priority Critical patent/JP7717765B2/ja
Application granted granted Critical
Publication of JP7346408B2 publication Critical patent/JP7346408B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020530675A 2017-12-06 2018-12-05 非アルコール性脂肪性肝炎を処置するための脂肪酸誘導体 Active JP7346408B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023144093A JP7717765B2 (ja) 2017-12-06 2023-09-06 非アルコール性脂肪性肝炎を処置するための脂肪酸誘導体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NO20171945 2017-12-06
NO20171944 2017-12-06
NO20171944 2017-12-06
NO20171945 2017-12-06
US201862743013P 2018-10-09 2018-10-09
US62/743,013 2018-10-09
PCT/IB2018/001459 WO2019111048A1 (en) 2017-12-06 2018-12-05 Fatty acid derivatives for treating non-alcoholic steatohepatitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023144093A Division JP7717765B2 (ja) 2017-12-06 2023-09-06 非アルコール性脂肪性肝炎を処置するための脂肪酸誘導体

Publications (3)

Publication Number Publication Date
JP2021505591A JP2021505591A (ja) 2021-02-18
JP2021505591A5 true JP2021505591A5 (https=) 2022-01-06
JP7346408B2 JP7346408B2 (ja) 2023-09-19

Family

ID=65012040

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020530675A Active JP7346408B2 (ja) 2017-12-06 2018-12-05 非アルコール性脂肪性肝炎を処置するための脂肪酸誘導体
JP2023144093A Active JP7717765B2 (ja) 2017-12-06 2023-09-06 非アルコール性脂肪性肝炎を処置するための脂肪酸誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023144093A Active JP7717765B2 (ja) 2017-12-06 2023-09-06 非アルコール性脂肪性肝炎を処置するための脂肪酸誘導体

Country Status (18)

Country Link
US (2) US11925614B2 (https=)
EP (1) EP3720431B1 (https=)
JP (2) JP7346408B2 (https=)
KR (1) KR20200096791A (https=)
CN (1) CN111712240A (https=)
AU (2) AU2018381124B2 (https=)
BR (1) BR112020011431A2 (https=)
CA (1) CA3084728A1 (https=)
CL (1) CL2020001504A1 (https=)
ES (1) ES2996688T3 (https=)
HR (1) HRP20241643T1 (https=)
HU (1) HUE069832T2 (https=)
IL (2) IL308604B2 (https=)
MX (1) MX2020005621A (https=)
PH (1) PH12020550784A1 (https=)
PT (1) PT3720431T (https=)
SG (1) SG11202005007VA (https=)
WO (1) WO2019111048A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2980790T3 (es) 2015-04-28 2024-10-03 Basf As Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP2020532551A (ja) 2017-09-03 2020-11-12 アンジオン バイオメディカ コーポレーション Rho関連コイルドコイルキナーゼ(ROCK)阻害剤としてのビニルヘテロ環
IL308604B2 (en) 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
KR20220017917A (ko) 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
CN114470217B (zh) * 2020-11-24 2023-06-20 深圳微芯生物科技股份有限公司 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物
WO2022137125A1 (en) 2020-12-22 2022-06-30 Northsea Therapeutics B.V. Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis
MX2023010537A (es) * 2021-03-08 2023-11-28 Abionyx Pharma Sa Compuestos útiles para tratar enfermedades del hígado.
CN113855812B (zh) * 2021-12-01 2022-03-11 上海翰森生物医药科技有限公司 聚乙二醇洛塞那肽或其药物组合物的新医药用途
JP2025541481A (ja) 2022-12-20 2025-12-18 ティーエイチファーム コーポレーション ナトリウム-グルコース共輸送体-2阻害剤およびアンジオテンシンii受容体遮断剤を含む非アルコール性脂肪性肝疾患の予防または治療用薬学的組成物
WO2025106728A1 (en) * 2023-11-14 2025-05-22 The Saban Research Institute; Children's Hospital Los Angeles Uses of lysophosphatidic acid receptor 1 antagonists
WO2025254426A1 (ko) 2024-06-03 2025-12-11 주식회사 티에치팜 엠파글리플로진 및 텔미사르탄을 함유하는 대사이상 관련 지방성 간질환 예방 또는 치료용 약학적 조성물
KR20250178400A (ko) * 2024-06-19 2025-12-29 한국과학기술연구원 홍삼박 유래 진토닌을 유효성분으로 포함하는 지방간 질환의 예방, 개선, 또는 치료용 조성물
CN119019255A (zh) * 2024-08-16 2024-11-26 合肥工业大学 一种dha分子活性探针及其制备方法和应用

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909554A (en) 1956-07-23 1959-10-20 Monsanto Chemicals Process for the manufacture of (alkylmercapto) alkyl sulfates
JPS4839001B1 (https=) 1970-11-09 1973-11-21
US4040781A (en) 1974-06-06 1977-08-09 Lever Brothers Company Novel 2-(alkylsulfinyl)ethyl sulfates and compositions employing same
US4032564A (en) 1974-09-09 1977-06-28 Zoecon Corporation Esters of cyclopropylalkanols
GB1523276A (en) 1974-09-20 1978-08-31 Lafon Labor Sulphur-containing amino compounds
US4009211A (en) 1975-07-29 1977-02-22 Gulf Research & Development Company Beta,beta-dialkylethylmercaptoethoxylate as new compounds
US4209410A (en) 1976-04-28 1980-06-24 Phillips Petroleum Company Lubricants
DE2861974D1 (en) 1977-11-11 1982-09-16 Ciba Geigy Ag Pyridine dicarboxylic acid derivatives, their mixtures with metallic stabilisers and their use in stabilising chlorine-containing thermoplasts
JPS5570841A (en) 1978-11-24 1980-05-28 Konishiroku Photo Ind Co Ltd Forming method of dye image
US4368190A (en) 1980-04-17 1983-01-11 Merck & Co., Inc. Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation
EP0050327B1 (de) 1980-10-21 1984-06-20 Roche Diagnostics GmbH Neue schwefelhaltige Phospholipide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4411808A (en) 1982-08-04 1983-10-25 Exxon Research & Engineering Co. Multifunctional additive for power transmission shift fluids
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4775223A (en) 1984-09-20 1988-10-04 Canon Kabushiki Kaisha Lactic acid derivative, liquid crystal composition containing same and liquid crystal device
CA2010000A1 (en) 1989-04-07 1990-10-07 Paul B. Merkel Photographic recording material containing a cyan dye-forming coupler
JPH0451149A (ja) 1990-06-19 1992-02-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
FR2663928B1 (fr) 1990-06-27 1994-04-08 Norsolor Nouveaux composes acryliques soufres, un procede pour leur preparation et leur application a la synthese de nouveaux polymeres.
EP0487809A1 (en) 1990-11-28 1992-06-03 Monsanto Europe S.A./N.V. Rubber compositions having improved processability and improved rubber-vulcanisate properties
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
JPH0543529A (ja) 1991-08-10 1993-02-23 Taisho Pharmaceut Co Ltd アルカンアミドアンモニウム化合物
JP2793458B2 (ja) 1992-03-19 1998-09-03 三井化学株式会社 コネクター用ポリアミド系樹脂組成物およびコネクター
JP2755279B2 (ja) 1992-03-19 1998-05-20 三井化学株式会社 熱可塑性樹脂組成物およびその成形体
CA2164717C (en) 1993-06-10 2009-10-20 Louis S. Kucera Method of combatting hepatitis b virus infection
JP3110918B2 (ja) 1993-06-18 2000-11-20 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
GB2290789B (en) 1994-07-01 1998-09-16 Ciba Geigy Ag Titanium and zirconium complexes of carboxylic acids as corrosion inhibitors
JPH10507179A (ja) 1994-10-13 1998-07-14 ペプチド テクノロジー リミテッド 修飾ポリ不飽和脂肪酸
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
FR2741619B1 (fr) 1995-11-28 1998-02-13 Pf Medicament Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique
WO1997038688A1 (en) 1996-04-12 1997-10-23 Peptide Technology Pty. Limited Methods of treating immunopathologies using polyunsaturated fattyacids
US6060515A (en) 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
CN1248916A (zh) 1997-01-24 2000-03-29 加利福尼亚大学董事会 FXR、PPARα和LXRα激活剂恢复屏障功能、促进表皮分化和抑制增生的用途
AU4806497A (en) 1997-10-01 1999-04-23 Procter & Gamble Company, The Glyoxylic compound comprising one or more active ingredient
JPH11180929A (ja) 1997-12-19 1999-07-06 Asahi Glass Co Ltd エステル誘導体
WO1999058120A1 (en) 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
FR2786187B1 (fr) 1998-11-19 2001-11-09 Univ Paris Curie Composes du type 2-acylamino-2-deoxy-glucono-1,5-lactone, procede d'obtention, compositions les comportant et utilisations
FR2792312B1 (fr) 1999-04-15 2001-06-08 Oreal Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
JP2003500459A (ja) 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター 置換バイアリールエーテル化合物
AUPQ291499A0 (en) 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
NO328803B1 (no) 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
FR2828487B1 (fr) 2001-08-09 2005-05-27 Genfit S A Nouveaux composes derives d'acides gras, preparation et utilisations
JP2005514437A (ja) 2001-12-21 2005-05-19 スリーエム イノベイティブ プロパティズ カンパニー イオン対複合体を含む医薬用エアロゾル製剤
GB2383355A (en) 2001-12-22 2003-06-25 Schlumberger Holdings An aqueous viscoelastic fluid containing hydrophobically modified polymer and viscoelastic surfactant
GB0202002D0 (en) 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
WO2003064707A1 (en) 2002-01-31 2003-08-07 Tfl Ledertechnik Gmbh Compositions and its use for imparting water repellency to leather or furskins, textiles and other fibrous materials
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
FR2845991B1 (fr) 2002-10-16 2005-02-04 Pf Medicament Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
JPWO2004076404A1 (ja) 2003-02-28 2006-06-01 株式会社カネカ 2位に置換基を有する光学活性化合物の製造法
DE10326303A1 (de) 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
US20090215895A1 (en) 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
JP4563114B2 (ja) 2004-08-30 2010-10-13 出光興産株式会社 潤滑剤用添加剤
US20060252670A1 (en) 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
KR20070108194A (ko) 2005-03-08 2007-11-08 시바 스폐셜티 케미칼스 홀딩 인코포레이티드 특정 n-아실아미노메틸렌 포스포네이트에 의해 코팅된금속 산화물 나노입자
CN101213281B (zh) 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
WO2006117668A1 (en) 2005-05-04 2006-11-09 Pronova Biopharma Norge As Fatty acid analogues, i.e. dha derivatives for uses as a medicament
JP4315134B2 (ja) 2005-07-06 2009-08-19 セイコーエプソン株式会社 電子機器
US20070167529A1 (en) 2006-01-17 2007-07-19 Walton Rebecca A Antimicrobial compositions for treating fabrics and surfaces
ES2391305T3 (es) 2006-04-12 2012-11-23 Unilever N.V. Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel
EP1849449A1 (en) 2006-04-26 2007-10-31 3M Innovative Properties Company Filler containing composition and process for production and use thereof
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
US20080075692A1 (en) 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
MX2009004337A (es) 2006-11-01 2009-05-22 Pronova Biopharma Norge As Compuestos lipidos omega-3.
KR101438177B1 (ko) 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
WO2008053340A1 (en) 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
CN101225064A (zh) 2007-01-19 2008-07-23 上海汇瑞生物科技有限公司 一种制备β-硫杂-α-烷基脂肪酸的新方法
DE102007017179A1 (de) 2007-04-12 2008-10-23 Clariant International Ltd. Verfahren zur Herstellung von Alkylpolyglykolcarbonsäuren und Polyglykoldicarbonsäuren mittels Direktoxidation
WO2009056983A1 (en) 2007-10-31 2009-05-07 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
PE20100156A1 (es) 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009149496A1 (en) 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
FR2933006B1 (fr) 2008-06-27 2010-08-20 Inst Francais Du Petrole Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante
DK2315740T3 (en) 2008-07-08 2018-01-08 Catabasis Pharmaceuticals Inc Fatty Acid Acetylated Salicylates and Their Uses
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
SG175390A1 (en) * 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
BRPI1015120B8 (pt) 2009-05-08 2022-02-15 Basf As Composto lipídico alfa-substituídos, derivados de ácidos graxos beta-oxo poli-insaturados, composição farmacêutica e lipídica e métodos para produzir composto lipídico e ácido 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaeniloxi)butanóico
EP2248798A1 (en) 2009-05-08 2010-11-10 Pronova BioPharma Norge AS Novel lipid compounds
WO2011028689A1 (en) 2009-09-01 2011-03-10 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
EP2526084A1 (en) 2010-01-20 2012-11-28 Pronova BioPharma Norge AS Salicylate fatty acid derivatives
ES2618604T3 (es) 2010-11-05 2017-06-21 Pronova Biopharma Norge As Métodos de tratamiento usando compuestos lipídicos
WO2012115695A1 (en) 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
WO2014045293A1 (en) 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof
WO2013016531A2 (en) 2011-07-26 2013-01-31 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
EP2846779A4 (en) 2012-05-07 2015-12-16 Omthera Pharmaceuticals Inc STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
US9486433B2 (en) * 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MX377728B (es) * 2013-02-28 2025-03-11 Pronova Biopharma Norge As Composición que comprende un compuesto lípido, un triglicerido y un tensioactivo, y métodos de uso de la misma.
PL2961727T3 (pl) 2013-02-28 2017-06-30 Pronova Biopharma Norge As Sposób wytwarzania kwasu 2-((5Z,8Z, 11Z,14Z,17Z)-ejkoza-5,8,11,14,17-pentaenyloksy)butanowego
US9889108B2 (en) * 2013-03-15 2018-02-13 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) * 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2015053379A1 (en) * 2013-10-07 2015-04-16 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
US9814726B2 (en) * 2014-04-18 2017-11-14 Lg Chem, Ltd. Composition for preventing or treating fatty liver diseases
KR20180010181A (ko) 2015-04-01 2018-01-30 프로노바 바이오파마 너지 에이에스 Apo c3 의 저하를 위한 티아 옥소 화합물의 용도
ES2980790T3 (es) 2015-04-28 2024-10-03 Basf As Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica
IL308604B2 (en) * 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis

Similar Documents

Publication Publication Date Title
JP2021505591A5 (https=)
IL275002B1 (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis
KR102419458B1 (ko) Acc 억제제를 포함하는 조합 요법
JP2019203003A (ja) 腸透過性亢進を治療するための組成物及び方法
IL266530B1 (en) Aramchol for use in fibrosis treatment
JP2011521992A (ja) アトルバスタチン4−(ニトロキシ)ブチルエステルおよび脂質低下剤を含む組成物
JP2024095711A (ja) 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
JP2020516622A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
JP2019516709A5 (https=)
US20100204249A1 (en) Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
US9925204B2 (en) Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation
JP2023554524A5 (https=)
JP2023554524A (ja) 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法
EP4248957A8 (en) Method for treating non-alcoholic steatohepatitis through co-administration of curcumin derivative and tgf-beta receptor inhibitor
El Bialy et al. Current progress in antifibrotics
JP2021526552A (ja) 血糖制御を改善し、炎症性腸疾患を処置するための構造修飾脂肪酸
KR20100109840A (ko) 분비성 포스포리파제 a2 (spla2) 억제제를 사용한 심혈관 질환 및 이상지혈증의 치료 및 spla2 억제제 조합 요법
KR20040032922A (ko) 신규 조합 제제
RU2022104049A (ru) Комбинированное лечение заболеваний печени агонистами fxr
NZ748675A (en) Method of treating liver fibrosis
US20110301202A1 (en) Spla2 inhibitor conjugate compounds and methods of use